Page last updated: 2024-11-04

dipropylenetriame

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(3-aminopropyl)-1,3-propanediamine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5942
CHEMBL ID28743
CHEBI ID16841
SCHEMBL ID15387
MeSH IDM000598200

Synonyms (99)

Synonym
wln: z3m3z
caldine
4-azaheptane-1,7-diamine
3,3'-iminobis[propylamine]
1,7-diamino-4-azaheptane
3,3'-iminobis(propylamine)
initiating explosive iminobispropylamine
dipropylamine,3'-diamino-
aminobis(propylamine)
iminobis(propylamine)
n-(3-aminopropyl)-1,3-propanediamine
3,3'-diaminodipropylamine
n-3-aminopropyl-1,3-diaminopropane
imino-bis(3-propylamine)
nsc-7773
p 2 (hardener)
nsc7773
dipropylenetriamine
1-propanamine,3'-iminobis-
propylamine,3'-iminobis-
1, n-(3-aminopropyl)-
3,3'-iminodi(propylamine)
3,3-diaminodipropylamine
n-(3-aminopropyl)propane-1,3-diamine
CHEBI:16841 ,
3,3'-azanediyldi(propanamine)
3,3'-iminodipropylamine
dipropylentriamin [german]
propylamine, 3,3'-iminobis-
un2269
1-propanamine, 3,3'-iminobis-
1,3-propanediamine, n-(3-aminopropyl)-
nsc 7773
ai3-25361
ccris 4826
brn 1071254
einecs 200-261-2
dipropylamine, 3,3'-diamino-
bis-(3-aminopropyl)amine
dipropylenetriamine (van)
norspermidine ,
56-18-8
3,3'-iminobispropylamine
bis(3-aminopropyl)amine
C03375
bis(3-aminopropyl)amine, 98%
D0090
CHEMBL28743 ,
NSD ,
4-azaheptamethylenediamine
3,3''-iminobis(propylamine)
bdbm50009367
3,3''-azanediyldi(propanamine)
3,3''-iminodi(propylamine)
n'-(3-aminopropyl)propane-1,3-diamine
dipropylentriamin
1,3-propanediamine, n1-(3-aminopropyl)-
bis(3,3'-aminopropyl)amine
3,3'-diaminopropylamine
3,3'-iminodipropylamine [un2269] [corrosive]
unii-rn1144mgnd
dipropylenetriame
ec 200-261-2
4-04-00-01278 (beilstein handbook reference)
rn1144mgnd ,
NCGC00260393-01
dtxcid505440
dtxsid0025440 ,
cas-56-18-8
tox21_202847
AKOS006223909
1,5,9-triazanonane
dipropylenetriamine [inci]
di(3-aminopropyl)amine
1,3-propanediamine,n-(3-aminopropyl)-
SCHEMBL15387
3,3'-iminobis-propylamine
dipropylene triamine
n,n-bis-(3-amino-propyl)-amine
n,n-bis(3-aminopropyl)amine
un 2269
3,3'-iminopropylamine
W-109255
mfcd00008214
bis(3-aminopropyl)amine, purum, >=97.0% (gc)
3, {3'-iminobis[propylamine]}
initiating explosive iminobispropylamine (dot)
n-(3-aminopropyl)-1, 3-propanediamine
n-3-aminopropyl
-1,3-propanediamine
3, 3'-diaminodipropylamine
3,3'-diamino-dipropylamine
3,3'-iminobis-1-propanamine
Q3878510
AMY14287
n1-(3-aminopropyl)propane-1,3-diamine
EN300-113765
STR03128
Z1203577926

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" In this study, silver ion, a conventional inorganic biocide, was combined with norspermidine and used for control and removal of multi-species biofilms formed by a mixed culture from wastewater treatment systems."( A small molecule norspermidine in combination with silver ion enhances dispersal and disinfection of multi-species wastewater biofilms.
Quan, X; Si, X; Wang, X; Wu, Y, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
polyazaalkaneAny azaalkane in which two or more carbons in the chain are replaced by nitrogen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency69.06650.002541.796015,848.9004AID1347395; AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency11.74230.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency21.10020.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency60.32720.000221.22318,912.5098AID743035; AID743036; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency35.75630.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency78.13430.003041.611522,387.1992AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency62.59630.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency62.06420.001530.607315,848.9004AID1224841
farnesoid X nuclear receptorHomo sapiens (human)Potency62.59630.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency23.62570.000229.305416,493.5996AID743069; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency56.15910.001024.504861.6448AID743212; AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency60.84550.023723.228263.5986AID743223; AID743241
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency62.06420.001723.839378.1014AID743083
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency60.33360.000323.4451159.6830AID743065; AID743066; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency11.84920.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Deoxyhypusine synthaseRattus norvegicus (Norway rat)IC50 (µMol)41.00000.03001.76503.5000AID56588
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID309803Effect on thermal melting point of herring testes DNA at 10 uM2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Construction of polyamine-modified uridine and adenosine derivatives--evaluation of DNA binding capacity and cytotoxicity in vitro.
AID56588In vitro IC50 value by measuring the inhibition of deoxyhypusine synthase.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Diamine and triamine analogs and derivatives as inhibitors of deoxyhypusine synthase: synthesis and biological activity.
AID44876Growth inhibition was measured against CHO cell line.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Diamine and triamine analogs and derivatives as inhibitors of deoxyhypusine synthase: synthesis and biological activity.
AID1272806Binding affinity to duplex DNA1(AP)/DNA2(C) (unknown origin) assessed as APE1 catalyzed beta-elimination product formation by gel electrophoresis2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
DNA cleavage at the AP site via β-elimination mediated by the AP site-binding ligands.
AID210118Inhibition of spermidine transport determined in T-47D human breast cancer cells2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Xylylated dimers of putrescine and polyamines: influence of the polyamine backbone on spermidine transport inhibition.
AID96533Percentage of spermine after 48 hr exposure to the compound (0.9 uM ) in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID86842Ability to inhibit 50% growth of HeLa cells1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and DNA-binding properties of polyamine analogues.
AID671760Binding affinity to DNA 5'-d GCG TAC AP CAT GCG-3' 3'-d CGC ATG T GTA CGC-5' assessed as equilibrium association constant by SPR analysis in presence of 50 mM NaCl2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and binding properties of new selective ligands for the nucleobase opposite the AP site.
AID98950Effect on ornithine decarboxylase (ODC) tested at 1 uM at 4 hour in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID97537Effect on S-Adenosyl-methionine decarboxylase (AdoMetDC) tested at 1 uM at 6 hour in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID309808Toxicity in human L56BrC1 cells after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Construction of polyamine-modified uridine and adenosine derivatives--evaluation of DNA binding capacity and cytotoxicity in vitro.
AID96677Percentage of spermine after 48 hr exposure to the compound (4.5 uM ) in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID160318Binding affinity values for polyamine transporter was determined1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID96513Percentage of spermidine after 48 hr of exposure to the compound (0.9 uM ) in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID1131174Metal chelate stability constant of the compound assessed as copper ion complex formation1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Antibacterial N-[omega, omega'-bis(alicyclic and aryl)-sec-alkyl]poly(methylene)triamine and -tetramine hydrochloride salts.
AID97152Effect on Spermidine/Spermine-Acetyltransferase (SSAT ) at 10 uM at 48 hour in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID100045Tested for the T/C (survival time treated /survival time control x 100) after intraperitoneal administration of 25 mg/kg in 10 E 5 L1210 cells on day 01990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Polyamine analogues with antitumor activity.
AID96526Percentage of spermidine after 48 hr of exposure to the compound (4.5 uM ) in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID96493Percentage of putrescine after 48 hr exposure to the compound (0.9 uM ) in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID98716Growth inhibitory activity against L1210 cells (96h)1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID162413Ability to displace ethidium bromide from double stranded synthetic Poly (dA-dT)1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and DNA-binding properties of polyamine analogues.
AID160317Binding affinity to the mouse polyamine transporter on the L1210 cell surface2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Molecular requirements for targeting the polyamine transport system. Synthesis and biological evaluation of polyamine-anthracene conjugates.
AID162553Ability to displace ethidium bromide from double stranded synthetic poly (dG-dC)1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and DNA-binding properties of polyamine analogues.
AID309807Toxicity in human HCC1937 cells after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Construction of polyamine-modified uridine and adenosine derivatives--evaluation of DNA binding capacity and cytotoxicity in vitro.
AID98715Growth inhibitory activity against L1210 cells (48h)1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID309809Toxicity in human SKBR3 cells after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Construction of polyamine-modified uridine and adenosine derivatives--evaluation of DNA binding capacity and cytotoxicity in vitro.
AID96506Percentage of putrescine after 48 hr exposure to the compound (4.5 uM ) in L1210 cells1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.
AID54444Ability to displace ethidium bromide from calf thymus DNA1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and DNA-binding properties of polyamine analogues.
AID87901Ability to cause aggregation of purified HeLa cell DNA1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and DNA-binding properties of polyamine analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (73)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (15.07)18.7374
1990's12 (16.44)18.2507
2000's12 (16.44)29.6817
2010's33 (45.21)24.3611
2020's5 (6.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.54 (24.57)
Research Supply Index4.34 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other75 (98.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]